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  13 
Introduction 14 
For over a decade, the measurement of cardiac biomarkers has been reported in cats with a variety 15 
of cardiac and systemic diseases, and measurement of N-terminal pro-B type natriuretic peptide 16 
(NTproBNP) and cardiac troponin I (cTnI) has now become commonplace in general and referral 17 
practice. The diagnosis of cardiac disease in cats poses particular challenges to many practitioners, 18 
including a high prevalence of sub-clinical (or “occult”) cardiomyopathy, the inconsistent implications 19 
of a heart murmur in asymptomatic cats of different ages, and a tendency for the first clinical signs of 20 
heart failure to be sudden onset and severe. These assays offer a straightforward and accessible test, 21 
which often feature in the diagnostic investigation of feline cardiac disease by vets in general and 22 
referral practice alike. However, our understanding of the clinical utility of these laboratory tests is 23 
ever evolving.  24 
This review aims to update the reader on the published veterinary literature regarding cardiac 25 
biomarkers in cats. The physiology of the natriuretic peptides and cardiac troponins is reviewed in 26 
detail elsewhere,1, 2 and the focus of this review will be on the role of cardiac biomarkers in clinical 27 
decision-making. 28 
 29 
Review Methods 30 
Published literature was searched using Medline, Web of Science and Google Scholar electronic 31 
databases.a,b,c Terms used in various combinations are listed in Table 1. The reference lists of retrieved 32 
articles were also manually searched and relevant citations retrieved. Conference proceedings were 33 
not included. Information recorded from each publication included citation details; biomarkers 34 
measured; the assay used; the number of animals, and the hypothesis, findings, conclusions and 35 
limitations of each study. This was then cross-checked by a second party for errors. 36 
A summary of the studies reviewed in this manuscript is tabulated (Tables 2-5) for quick reference. 37 
This review initially considers biomarkers measured in reference laboratories. Some of the newer, 38 
point-of-care tests are considered later in this manuscript. 39 
 40 
Distinguishing cardiac from non-cardiac causes of respiratory distress 41 
Cats with respiratory distress are often unstable and tolerate poorly any handling or diagnostic 42 
interventions. Although useful to identify cats with cardiogenic respiratory distress, echocardiography 43 
may not be available. Measurement of a cardiac biomarker may be useful if a blood sample can be 44 
obtained with minimal restraint, and this may be safer than thoracic radiography. Eight studies were 45 
identified that compared cardiac biomarker concentrations in cats with cardiac and non-cardiac 46 
causes of respiratory distress: 4 studies investigated cTnI3-6 and 4 investigated natriuretic peptides (of 47 
which, all 4 featured NTproBNP and 1 featured NTproANP)7-10 (Table 2). 48 
Of the cTnI studies, 3/4 reported a higher median cTnI concentration in the cardiac vs. the non-cardiac 49 
group and one failed to detect a statistically significant difference. The study where no difference was 50 
detected3 also had the smallest sample size, so this finding may reflect that the statistical comparison 51 
was under-powered. All studies where a difference was identified reported a considerable overlap in 52 
cTnI values between cardiac and non-cardiac groups, suggesting that a single cut-off value to identify 53 
cardiogenic dyspnea in cats is unlikely to be clinically useful. 54 
In contrast, NTproBNP has shown greater accuracy in distinguishing cats with cardiac dyspnea from 55 
those with non-cardiac causes: all 4 studies reviewed reported higher median NTproBNP 56 
concentration in cats with cardiogenic respiratory distress.7-10 The one study investigating NTproANP 57 
reported that the overall accuracy of this test was lower than NTproBNP, but despite this, the test was 58 
still useful to detect cardiogenic dyspnea.8 Published NTproBNP cut-off values for identifying cats with 59 
acute congestive heart failure range from 214-277 pmol/L, with a sensitivity generally over 85% and a 60 
specificity of 84-88%. However, because these studies were published over a 5 year time frame and 61 
used 3 different commercially available assays, the cut-off values and sensitivity/specificity data 62 
should not be directly compared. Also, recent changes in commercial assay methodology may mean 63 
that established cut-off values are replaced by new publications using contemporary assays. Despite 64 
this, the evidence convincingly supports the use of NTproBNP to differentiate between cardiac and 65 
non-cardiac causes of respiratory distress in cats. A significant practical limitation of the published 66 
literature is the current lack of studies investigating the utility of a patient-side NTproBNP test, which 67 
has only recently become available. 68 
 69 
Pleural fluid and urinary NTproBNP measurement 70 
In humans, NTproBNP concentration can be accurately measured in pleural fluid and urine.11, 12 The 71 
same has been shown in 40 cats presenting to an emergency department with pleural effusions.10 In 72 
both urine and pleural effusion samples, NTproBNP was detectable with adequate performance. 73 
NTproBNP concentration was significantly higher in pleural fluid than in plasma with a strong 74 
correlation between measurements, suggesting that measurement of NTproBNP in pleural fluid 75 
obtained during therapeutic thoracocentesis is an adequate and reliable substitute for blood 76 
sampling, thereby reducing handling of these dyspneic patients. Urine NTproBNP to creatinine ratio 77 
was higher in the cats with cardiogenic pleural effusion than those with noncardiac causes. Despite 78 
this, further analysis failed to determine useful cut-off values to distinguish between cardiac and 79 
noncardiac patients using urinary NTproBNP, possibly related to variable handling or processing time 80 
for urine samples in the study. Further studies with improved standardisation of urine sample 81 
collection from cats with suspected cardiac disease are needed. 82 
 83 
Identification of cats with occult cardiomyopathy 84 
Occult heart disease is common in cats, and currently most cats are screened by a veterinary 85 
cardiologist using echocardiography. However, some cat owners may be reluctant to travel or pay for 86 
a cardiologist to perform echocardiography, highlighting a possible role for cardiac biomarkers to pre-87 
screen for cats most likely to benefit from echocardiography. Eleven published studies compared a 88 
control group of healthy cats to a group of cats with echocardiographic evidence of heart disease, but 89 
no clinical signs of congestive heart failure3, 13-21 (Table 3). Of these, only the 2 largest studies were 90 
specifically designed to test the ability of cardiac biomarkers to identify occult cardiomyopathy in a 91 
screened population of cats. One investigated the use of a quantitative NTproBNP assay,16 whilst the 92 
second evaluated a patient-side SNAP colorimetric assay.21 In all, the 10 published studies describe a 93 
total of 393 healthy cats, 350 cats with HCM, 38 with RCM or UCM, 5 with DCM and 1 with ARVC. 94 
Broadly, all but one of these studies reported that cardiac biomarkers were significantly higher in cats 95 
with echocardiographic evidence of cardiomyopathy than in cats without cardiac disease. 96 
In three studies, NTproANP was reported to be significantly higher in cats with echocardiographic 97 
evidence of heart disease than healthy controls in 3 studies.18-20 In contrast, one small study17 did not 98 
detect a significant difference between cats with and without heart disease but reported a weak 99 
positive correlation between NTproANP and left atrial size. 100 
NTproBNP has been reported to be significantly higher in cats with heart disease than healthy cats in 101 
all 5 studies reporting this comparison. Three studies report an optimal NTproBNP cut-off value for 102 
detecting occult cardiomyopathy: 2 studies identified 100pmol/L (71-92% sensitivity, 94-100% 103 
specificity),15, 16 the third identified 49pmol/L (sensitivity 100%, specificity 89%).19 However, in those 104 
studies that tested the ability of NTproBNP to distinguish between different grades of severity of 105 
cardiomyopathy,14-16, 21 this biomarker was less accurate at identifying mild grades of disease. This 106 
suggests that echocardiography remains preferable to screen for mild/early stage disease. In one 107 
study, Maine Coons positive for the MYBPC3:A31P mutation had significantly higher NTproBNP than 108 
mutation-negative cats.14 109 
Both studies comparing cTnI in cats with heart disease (no heart failure) to healthy controls reported 110 
that circulating concentrations of this biomarker were significantly higher in cats with heart disease,3, 111 
13 as did a recent validation study for a high sensitivity cTnI assay.22 However, with the larger samples 112 
sizes reported and the similarities in results between the published studies, NTproBNP currently 113 
seems the better cardiac biomarker to use when screening for occult cardiomyopathy. 114 
 115 
Effects of systemic disease 116 
In humans, circulating cardiac biomarker concentrations are known to be influenced by age, sex, renal 117 
and thyroid function, body condition (especially obesity) and the presence of anemia.23 Although the 118 
effects of body weight, age and sex have not been well studied in cats, the effects of some non-cardiac 119 
diseases have been investigated. Six published studies evaluated the effects of non-cardiac, non-120 
respiratory disease on circulating cardiac biomarkers (Table 4). Three investigated hyperthyroid 121 
cats,24-26 2 investigated chronic kidney disease (CKD, plus/minus hypertension),27,28 and 1 reported 122 
preliminary data in anaemic cats.29 All 3 studies regarding the effect of hyperthyroidism provided 123 
strong evidence that NTproANP (n=61),25 NTproBNP (n=84)25, 26 and cTnI (n=46)24, 26 are increased in a 124 
hyperthyroid state and return to the same level as non-hyperthyroid controls after restoration of a 125 
euthyroid state by radioactive iodine therapy. Only one of these studies26 compared hyperthyroid cats 126 
to separate control groups of normal cats and a separate group of cats with cardiomyopathy. In this 127 
study, both NTproBNP and cTnI were higher in cats with cardiomyopathy than hyperthyroidism, but 128 
significant overlap was present between groups, suggesting that neither biomarker can effectively 129 
differentiate between cats with hyperthyroidism and primary cardiomyopathy. The consistent finding 130 
that cTnI is increased in hyperthyroid cats suggests that not only are cardiac filling pressures affected 131 
by changes in systemic vascular resistance and circulating volume induced by the endocrinopathy, but 132 
that thyrotoxicosis affects the myocardium on a cellular level to cause myocardial cell damage (either 133 
by a direct effect of thyroid hormones or an indirect effect, for example via sympathetic nervous 134 
system activation). 135 
In cats with azotemic CKD, cTnI is commonly higher than the reference interval for healthy cats. 136 
However, no correlation between the severity of azotemia and the degree of cTnI elevation was 137 
present, suggesting that the azotemic state may be more important than the degree of renal 138 
functional impairment when comparing individual cats to reference intervals.27 However, the results 139 
of this study merit some additional research, because no control group was used and none of the 14 140 
cats investigated had echocardiography performed. 141 
Natriuretic peptides have also been evaluated in cats with CKD. One study reported values of 142 
NTproANP and NTproBNP in cats with CKD (with and without hypertension) and compared them to a 143 
control group of non-hypertensive cats without evidence of CKD.28 NTproBNP was significantly higher 144 
in cats with severe azotemia (>440umol/L or 5mg/dL) than those with less severe CKD and healthy 145 
controls but, again, no correlation with creatinine concentration was detected. Also, NTproBNP was 146 
higher in hypertensive CKD than non-hypertensive cats with CKD, and circulating concentrations 147 
reduced after successful treatment of hypertension. Similarly to NTproBNP, NTproANP was higher in 148 
severely azotemic cats and those with hypertension. However, unlike NTproBNP, NTproANP did 149 
correlate with serum creatinine concentration and did not normalise with treatment of systemic 150 
hypertension. The reasons for these differences are unclear, but this and the findings of several other 151 
studies suggest that NTproBNP is more sensitive to dynamic changes than NTproANP. As with the cTnI 152 
study above,27 this study of natriuretic peptides in cats with CKD did not include echocardiographic 153 
examination of any of the subjects. Also, the control group was not age-matched with the 154 
hypertensive and non-hypertensive CKD groups. These weaknesses mean that further, prospective, 155 
standardised studies in cats with CKD ± hypertension are warranted, where echocardiography is 156 
performed to account for the presence of occult cardiac disease and where a control group is age- and 157 
sex-matched to the cats with CKD. 158 
One recent study investigating the effect of anemia on cTnI in cats showed that anemic cats had 159 
significantly higher circulating cTnI than a control population of unwell, non-anemic cats.29 However, 160 
this study was subject to similar methodological flaws, in that echocardiography was not performed 161 
on all cats and the authors did not report the frequency with which auscultated abnormalities (such 162 
as a gallop sound, arrhythmia or murmur) were present in the anaemic group. Cats with auscultated 163 
abnormalities were, however, excluded from the control group of non-anaemic cats. 164 
 165 
Point of care tests 166 
Much interest has been expressed in developing patient-side cardiac biomarker assays, primarily for 167 
use in cats with respiratory distress, in the hope that this may help practitioners more confidently 168 
diagnose and treat acute congestive heart failure (CHF). Another potential application for these in-169 
clinic tests would be to help primary clinicians stratify cats with heart murmurs, according to which 170 
are most likely to have occult cardiomyopathy and therefore require echocardiography. Two studies 171 
evaluating patient-side cardiac biomarker tests in cats with cardiac disease have been published.6, 21 172 
The performance of the first patient-side NTproBNP ELISA (IDEXX Ltd) was tested in a recent study of 173 
146 cats.21 The ability of this colorimetric test to identify cats with moderate to severe heart disease 174 
amongst a population of cats referred for cardiac investigation suggested a good performance in 175 
identifying moderate and severe grades of occult heart disease. The assay had a positive cut-off 176 
NTproBNP concentration of between 108-122pmol/L, similar to the cut-off of 100pmol/L for detection 177 
of moderate/severe occult cardiomyopathy previously reported.16 The negative predictive value (NPV) 178 
of the patient-side test was 94%; i.e. in a cat with a negative test result, there was a 94% probability 179 
that this patient truly did not have moderate to severe heart disease. Although the positive predictive 180 
value (PPV) was only 64%, this also aids identification of a population of asymptomatic cats where 181 
echocardiography is indicated to screen for occult disease. These figures suggest that the patient-side 182 
test has significantly greater utility to “rule-out” more advanced heart disease than it does to confirm 183 
the presence of disease. The population described in this study had a high prevalence (24%) of 184 
moderate-severe heart disease. In a different population of lower prevalence, such as the background 185 
general practice population, the PPV would be even lower. Importantly however, the NPV of the test 186 
would increase. For example, if screening a population of shelter cats for hypertrophic 187 
cardiomyopathy (HCM), which has an estimated overall prevalence of 15%,30 the NTproBNP point of 188 
care test would have a PPV of 49% and an NPV of 97%, presuming the same test sensitivity and 189 
specificity. This would make it a useful test for identifying cats with none or mild disease, for which 190 
further diagnostic interventions such as echocardiography are unlikely to add significant additional 191 
information to the practitioner. A notable exception to this would be when screening cats used for 192 
breeding, where echocardiography would still be required to detect mildly affected cats. Also, the 193 
confounding influence of hyperthyroidism to increase circulating NTproBNP concentration should be 194 
considered in older cats where point-of-care testing is performed.25, 26 195 
To date, the ability of this point of care NTproBNP test to distinguish between cardiac and noncardiac 196 
causes of respiratory distress has not been evaluated. Despite this, it is reasonable to assume that a 197 
negative colorimetric test in a dyspneic cat is likely to reflect a noncardiac cause of clinical signs. In 198 
contrast, patient-side cTnI analysis has been investigated in 37 cats to identify cats with a cardiac cause 199 
of acute respiratory distress.6 In this study, cTnI was significantly higher in cats with cardiac disease 200 
than those with a respiratory cause of dyspnea. Cats with a circulating cTnI concentration below 201 
0.24ng/mL all had a noncardiac cause of clinical signs, whereas above 0.66ng/mL all cats had 202 
cardiogenic dyspnea. In this population, none of the cats had sepsis such as pyothorax as a cause of 203 
dyspnea. Sepsis is known to increase circulating cTnI concentrations in humans and dogs31-33 and the 204 
same may be true in cats. If so, the findings of this study may not be applicable to a wider population 205 
of cats which included patients with pyothorax. 206 
 207 
Prognostic utility of cardiac biomarkers 208 
In humans, NTproBNP, cTnI and cTnT have been used to stratify patients with HCM according to 209 
prognosis.34-38 Three studies have been published investigating the association of cardiac biomarker 210 
concentration with outcome in cats with heart disease; one investigating NTproANP,39 one 211 
investigating both cTnI and cTnT,40 and one investigating NTproBNP and cTnI (Table 5).41 212 
NTproANP was the first cardiac biomarker evaluated for an association with survival time in cats with 213 
cardiomyopathy, in a study evaluating 68 cats with varying degrees of cardiomyopathy severity.39 214 
Although significant at the univariable level, NTproANP did not remain significant in multivariable 215 
analysis when included alongside echocardiographic measures of left atrial size, suggesting that once 216 
left atrial size was known, no additional prognostic information was gained by the measurement of 217 
NTproANP. Similarly, higher NTproBNP was associated with reduced survival time in cats with HCM at 218 
the univariable level, but did not remain additionally useful once clinical signs or left atrial size were 219 
accounted for in another study of 41 cats.41 220 
Cardiac troponins may be more useful than natriuretic peptides in providing prognostic information 221 
in cats. The circulating concentration of cTnI and cTnT at diagnosis were significantly higher in cats 222 
that suffered cardiac death than survivors in one recent study investigating 36 cats with HCM.40 cTnT 223 
was a better prognostic marker in this study, with cTnI showing no additional prognostic utility. Results 224 
also suggested that serial biomarker monitoring may be clinically useful, because cTnT measurement 225 
repeated before the end of the follow-up period in this cohort of cats provided independent 226 
prognostic information, even when accounting for cTnT concentration at the time of diagnosis. A 227 
second study, reporting 41 cats with HCM, identified this same association between increased cTnI 228 
and a greater risk of cardiac death.41 Cats with a circulating concentration of cTnI >0.7ng/ml at the 229 
time of diagnosis had a shorter time to cardiac death, independent of both clinical signs of congestive 230 
heart failure and echocardiographic measures of left atrial size or function. In this study, cats with 231 
regional LV hypokinesis detected on echocardiography had significantly higher cTnI than cats without 232 
regional hypokinesis, possibly reflecting an association between increased cTnI and regional 233 
myocardial ischemia or infarction. It is worth noting that these two studies40, 41 used different cTnI 234 
assays, so despite the similar patient demographics and the publication of these two articles within 235 
months of once another, reported cTnI values are not comparable. 236 
Currently, no published studies have thoroughly evaluated how cardiac biomarkers may change over 237 
time in cats with cardiomyopathy. One recently presented research abstract42 suggested that a >70% 238 
change in quantitative NTproBNP measurement was required to indicate a genuine change, instead 239 
of day-to-day biological or assay variability. In our own clinics, it is advised that an increased 240 
NTproBNP test (or positive patient-side SNAP test) be followed up with echocardiography rather 241 
than re-testing, so our personal experience with this is limited. In dogs, the rate of change in cardiac 242 
biomarker concentration appears important in long-term prognosis, but this has not been reported 243 
in cats and it is not understood how this may help to predict outcome in feline patients. 244 
 245 
Limitations 246 
Most of the studies reviewed here had a prospective design and investigative protocol was 247 
standardized where possible. However, treatment protocols were not standardized and differences in 248 
decision making between different veterinarians and different owners will no doubt have affected 249 
survival time in studies evaluating prognosis. 250 
No consensus exists amongst veterinary cardiologists as to how best grade severity of cardiomyopathy 251 
in cats, other than to say most cats that have experienced clinical signs of congestive heart failure have 252 
severe disease. In the screening studies reviewed here, where cats with cardiomyopathy were 253 
classified into groups of equivocal, mild, moderate and severe by some studies, this lack of consensus 254 
means that different authors classified cats in different ways. For example, severe cardiomyopathy in 255 
some groups took into account left atrial size but in others only accounted for degree of wall 256 
thickening. As a result, cats classified as “severe” by some studies may have been classified as 257 
“moderate” by others. This lack of consensus means that the reader cannot directly compare the 258 
findings of different screening studies utilising cardiac biomarkers. In addition, a lack of consensus and 259 
an inconsistency in the echocardiographic measurement technique between veterinary cardiologists 260 
means that even the current ‘gold-standard’ of diagnosing mild (or equivocal) HCM may not be reliably 261 
comparable between publications, and this may account for some of the differences in optimal 262 
NTproBNP cut-off values reported in different studies. 263 
Misclassification of patients into even broad groups is possible, such as presence or absence of cardiac 264 
disease, or suffering a cardiac versus noncardiac death. An example of this was identified by Humm 265 
and colleagues,10 who reported a suspected misclassification of one cat in their study, despite all 266 
patients having been assessed by a veterinary cardiologist using echocardiography. This may have led 267 
to falsely low specificity of pleural fluid NTproBNP to detect cardiogenic pleural effusion in their article. 268 
Other studies did not perform echocardiography on all cats included, so the presence of cardiac 269 
disease in many patients was not assessed, and some studies did not exclude patients with systemic 270 
hypertension or hyperthyroidism from their cardiac disease group. Although a heterogeneous 271 
population of cats is more likely to be reflective of the wider general practice population, 272 
misclassification of cases and the presence of concurrent systemic disease affecting the cardiovascular 273 
system are likely to reduce the discriminative ability of the cardiac biomarker tests reported in certain 274 
studies. This is especially true in studies with a small sample size or low event rate, such as is the case 275 
in many veterinary studies. 276 
Finally, two aspects of laboratory technique are important to consider. The use of different assays in 277 
different studies limits the utility of published cut-off values to clinicians comparing their measured 278 
biomarker concentration to those reported in the literature. This is especially important to note for 279 
cTnI, where 5 different assays were used across the 13 papers reviewed here. Another limitation is 280 
the difference between NTproBNP concentration measured by the “second generation” IDEXX Feline 281 
Cardiopet NTproBNP assay and the previous assay used by the same laboratory (although the 282 
manufacturer states that values are likely to be comparable). It is likely that studies published before 283 
2014 did not use the more sensitive second generation NTproBNP assay from IDEXX, so cut-off values 284 
may not apply to practitioners testing cats at the time of writing, even though they are using the same 285 
reference laboratory. 286 
 287 
Summary 288 
The published literature on cardiac biomarkers in cats is widespread, and recent studies have widened 289 
our understanding of the emerging roles for cardiac biomarkers in cats with heart disease, especially 290 
in relation to the development of the convenient patient-side assay and the use of these biomarkers 291 
for long-term prognosis. 292 
NTproBNP appears to most reliably differentiate between cardiac and noncardiac causes of 293 
respiratory distress in cats. Measurement of NTproBNP is reliable from pleural fluid obtained by 294 
thoracocentesis, without the need for blood sampling restraint in an unstable patient. The patient-295 
side test will increase the convenience of NTproBNP testing in cats in general practice and this test has 296 
great potential to assist in the emergency room. However, the usefulness of NTproBNP in 297 
prognostication is limited where left atrial dilation and a history of congestive heart failure can be 298 
reliably confirmed. In contrast, measurement of cTnI can be used not only as a patient-side test to 299 
differentiate cardiac from noncardiac causes of respiratory distress (albeit less accurately than 300 
NTproBNP), but can also be used as part of prognostication together with heart failure status and 301 
echocardiographic measurements. 302 
On the basis of current published data, future studies evaluating urinary NTproBNP:creatinine ratio as 303 
a diagnostic test are warranted. The value of the patient-side NTproBNP ELISA in distinguishing 304 
between cardiac and respiratory causes of respiratory distress has not yet been published, so its use 305 
in the acute patient would currently be based upon limited data. There is notable overlap between 306 
the NTproBNP concentrations reported in cats with respiratory disease and the established cut-off 307 
value used for the diagnosis of occult cardiomyopathy by the patient-side test, so the potential for 308 
false-positive results when using the point-of-care test in acute patients should be considered, as 309 
supported by data recently presented as a research abstract.  310 
The current evidence base for how systemic non-cardiac diseases affect the circulating concentrations 311 
of cardiac biomarkers is weak for cats with CKD and systemic hypertension, and further studies are 312 
warranted in these patients. However, hyperthyroid cats are relatively well studied and the evidence 313 
from which to draw conclusions is more reliable. 314 
In the authors’ opinions, practitioners should interpret absolute cut-off values from the published 315 
literature cautiously, due to differences in the commercial troponin assays used by different studies, 316 
and differences in NTproBNP assay sensitivity at reference laboratories. However, available results 317 
suggest that cardiac biomarkers will continue to have clinical utility for veterinary cardiologists and 318 
are likely to have an increasingly important role in both primary and referral veterinary practice. 319 
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Table 1: Search terms used in combination to review electronic online databases for recent 326 
published literature on feline cardiac biomarkers 327 
Search term Feline 
Cat 
Natriuretic 
Peptide 
Cardiac 
Troponin 
NTproBNP 
NT-proBNP 
NTproANP 
NT-proANP 
cTnI 
cTnT 
Cardiomyopathy 
Biomarker 
 328 
  329 
Table 2: Summary of the studies reporting the use of cardiac biomarkers to differentiate between 330 
cardiac and noncardiac causes of respiratory distress in cats 331 
cTnI, cardiac troponin I; NTproANP, N-terminal pro atrial natriuretic peptide; NTproBNP, N-terminal pro B-type natriuretic peptide;  AUC, 332 
area under the curve, pertaining to receiver operating curve statistical analysis of diagnostic test utility; P, prospective study design; M, 333 
multicenter recruitment; C, control group appropriate; B, blinding specified in manuscript; E, echocardiography on all cats 334 
Biomarkers Number of cats Conclusions Assay Citation Evidence 
category 
cTnI 
16 cats with HCM, 18 
healthy controls 
cTnI can help distinguish between 
HCM and non-HCM groups, but less 
able to identify cats with CHF 
Immulyte 
(Diagnostic 
Products Co.) 
Connolly3 P;C;E 
43 cats with dyspnea 
(31 cardiac) 
Able to identify cardiac causes of 
dyspnea: AUC 0.84. Overlap between 
groups 
Stratus (Dade 
Behring) 
Herndon4 P;M;C;E 
53 cats with dyspnea 
(23 cardiac) 
Significant difference between 
cardiac and noncardiac: AUC 0.84. 
Overlap between groups 
Immulyte 
(Siemens 
Medical 
Diagnostics) 
Connolly5 P;M;C 
39 dyspneic cats (25 
cardiac) 
37 healthy controls 
A patient-side cTnI assay can be used 
to differentiate cats with cardiac 
causes of dyspnea from those with 
noncardiac disease and normal 
controls 
i-Stat 1 analyser 
(Heska Corp.) 
Wells6 P;M;C;E 
NTproANP 
NTproBNP 
85 dyspneic cats (44 
cardiac) 
Both NTproANP and NTproBNP were 
able to discriminate between cardiac 
and noncardiac patients, but 
NTproBNP better performance (cut-
off 220pmol/L, AUC 0.96) 
proANP 1-98 
(Guildhay Ltd), 
Cardioscreen 
NTproBNP 
(Guildhay Ltd) 
Connolly8 P;C;B 
NTproBNP 
162 dyspneic cats (101 
cardiac) 
Reliable discrimination between 
cardiac and respiratory causes of 
dyspnea: cut-off 207pmol/L, AUC 0.98 
CardioPet 
proBNP (IDEXX 
Ltd) 
Fox7 P;M;C;E 
21 cats with pleural 
effusion (11 cardiac 
disease) 
NTproBNP successfully discriminated 
between cardiogenic and noncardiac 
causes of pleural effusion: cut-off 
258pmol/L, AUC 1.0 
Cardiopet 
proBNP (IDEXX 
Ltd) 
Hassdente
-ufel9 
P;C;B;E 
40 cats with pleural 
effusion (22 cardiac) 
Plasma NTproBNP reliably identified 
cats with cardiogenic pleural effusion: 
cut-off 214pmol/L, AUC 0.91 
Vetsign Feline 
Cardiopet 
NTproBNP 
(IDEXX Ltd) 
Humm10 P;C;E 
 335 
  336 
Table 3: Summary of the studies reporting the use of cardiac biomarkers to detect occult heart 337 
disease in cats 338 
cTnI, cardiac troponin I; NTproANP, N-terminal pro atrial natriuretic peptide; NTproBNP, N-terminal pro B-type natriuretic peptide;  AUC, 339 
area under the curve, pertaining to receiver operating curve statistical analysis of diagnostic test utility; P, prospective study design; M, 340 
multicenter recruitment; C, control group appropriate; B, blinding specified in manuscript; E, echocardiography on all cats 341 
Test Number of cats Conclusions Assay Citation Study 
design 
cTnI 
16 cats with HCM, 18 
healthy controls 
cTnI can help distinguish between 
HCM and non-HCM groups, but less 
able to identify cats with CHF 
Immulyte 
(Diagnostic 
Products Corp.) 
Connolly3 P;C;E 
53 cats: 20 HCM and 
33 healthy controls. 
cTnI could discriminate between HCM 
and control cats, and was also 
correlated with LV wall thickness 
Status CS 
troponin I (Dade 
Behring Inc.) 
Herndon13 P;M;B;C 
73 cats: 53 cardiac 
and 20 healthy 
controls 
cTnI was higher in cats with heart 
disease than control cats (assay 
validation study) 
  
ADVIA Centaur CP 
TnI-ultra 
(Siemens) 
Langhorn22 P;C;E 
NTproANP 
36 cats: 17 HCM and 
19 healthy controls 
No significant difference between 
HCM and control cats, but a mild 
positive correlation with LVFW 
thickness and LA size was detected 
proANP 1-98 
Biomedica, 
(American 
Laboratory 
Products Co.) 
Maclean17 P;B;C;E 
Study 1 - 5 cats 
Study 2 - 22 cats: 14 
cardiomyopathy and 
8 controls 
Positively correlated with LA 
pressure. Significant difference 
between cardiac and control groups 
Shinonoria-ANP 
radioimmunoassa
y (Shionogi Co.) 
Hori18 P;C;E 
43 cats: 16 heart 
disease/CHF, 16 
Positively correlated with LA size. 
Discriminated between all 3 groups 
proANP 1-98 
(Biomedica 
Zimmering20 P;B;C;E 
heart disease/NO-
CHF, 11 controls 
Group, 
Immundiagnostik 
AG) 
NTproANP 
NTproBNP 
78 cats: 33 heart 
disease/CHF, 17 
heart disease/NO-
CHF, 28 controls 
Both biomarkers distinguished 
between all 3 groups, and were 
correlated with each other. 
NTproBNP was more accurate at 
detecting cardiac disease: cut-off 
49pmol/L, AUC 0.98. Both markers 
positively correlated with LA size and 
E:E’ ratio. 
proANP 1-98 
(Guildhay Ltd) 
Feline 
Cardioscreen 
proBNP (Guildhay 
Ltd) 
Connolly19 P;B;C;E  
NTproBNP 
41 cats: 9 normal, 12 
equivocal HCM, 19 
moderate/severe 
HCM. Maine Coon or 
Maine Coon-cross 
only 
Higher NTproBNP in severe group, no 
significant difference between all 
other groups: not an effective 
screening test in this population. 
Severe HCM cut-off 44pmol/L, AUC 
not reported. MYBPC3:A31P 
mutation positive cats had higher 
NTproBNP 
Feline Cardiocare 
NTproBNP 
(Veterinary 
Diagnostics 
Institute) 
Hsu14 P;C;E 
201 cats: 99 normal, 
9 equivocal HCM, 15 
mild HCM, 17 
moderate HCM, 61 
severe HCM 
No difference in NTproBNP between 
equivocal and healthy cats. Severe 
HCM had significantly higher 
NTproBNP than other groups. Cut-off 
for mild HCM detection 100pmol/L, 
AUC 0.96 
Feline 
Cardioscreen 
proBNP (Guildhay 
Ltd) 
Wess15 P;C;B;E 
227 cats: 114 normal, 
87 HCM, 22 UCM, 3 
UCM, 1 DCM 
NTproBNP effectively discriminated 
between normal cats and those with 
occult cardiomyopathy. Cut-off 
Cardiopet proBNP 
(IDEXX Ltd) 
Fox16 P;M;C;B;E 
99pmol/L, AUC 0.92. Correlation of 
NTproBNP with LV wall thickness and 
LA size. 
146 cats: 43 normal, 
16 equivocal, 50 mild 
heart disease, 37 
moderate/severe 
NTproBNP SNAP test can be used to 
help exclude moderate to severe 
occult cardiomyopathy; negative 
predictive value 94% 
NTproBNP SNAP 
(IDEXX) 
Machen21 P;M;C;B;E 
 342 
  343 
Table 4: Summary of the studies reporting the use of cardiac biomarkers in patients with noncardiac 344 
disease 345 
cTnI, cardiac troponin I; NTproANP, N-terminal pro atrial natriuretic peptide; NTproBNP, N-terminal pro B-type natriuretic peptide; P, 346 
prospective study design; M, multicenter recruitment; C, control group appropriate; B, blinding specified in manuscript; E, 347 
echocardiography on all cats; RAI, radioactive iodine treatment; BP, blood pressure; PCV, packed cell volume 348 
 349 
Test Number of cats Conclusions Assay Citation Study 
design 
cTnI 23 hyperthyroid cats 
(18 post-treatment 
with RAI) 
cTnI higher in cats with higher total 
thyroxine concentration. Trend 
towards reduction in cTnI observed, 
but not statistically significant. 
Immulyte 
(Diagnostic 
Products Co.) 
Connolly24 P;B;E 
NTproBNP 
cTnI 
23 hyperthyroid cats 
(12 post-treatment 
with RAI), 17 cats 
with HCM, 19 
controls 
cTnI was increased in 46% and 
NTproBNP was increased in 38% 
hyperthyroid cats with no 
echocardiographic abnormalities. 
Both biomarkers normalised in most 
hyperthyroid cats after RAI 
treatment. 
Cardiopet 
NTproBNP 
(IDEXX), Stratus 
CS Stat cTnI 
(Dade Behring) 
Sangster26 P;C;B;E 
NTproANP 
NTproBNP 
 
85 hyperthyroid cats 
at baseline, 61 post-
treatment with RAI 
Hyperthyroidism was associated with 
a significant but modest elevation of 
both natriuretic peptides, which 
reduced after RAI treatment. 
Cardiopet 
NTproBNP 
(IDEXX) 
Menaut25 P;M 
cTnI 14 cats with CKD cTnI higher in azotemic patients, but 
no correlation with creatinine 
concentration 
Stratus CS Stat 
cTnI (Dade 
Behring) 
Porciello27  
NTproANP 
NTproBNP 
 
58 cats: 22 normal, 
13 CKD 
normotensive, 23 
CKD hypertensive 
NTproBNP higher in cats with severe 
azotemia, but no correlation with 
creatinine. NTproBNP was higher in 
hypertensive CKD than non-
hypertensive CKD. Also correlated 
with systolic BP and age. NTproBNP 
reduced after treatment of 
hypertension. NTproANP similar, but 
did not reduce after treatment.  
NTproANP 1-
98, (Biomedica 
Gruppe), 
VETSIGN Feline 
Cardio-SCREEN 
proBNP, 
(Guildhay Ltd) 
Lalor28 M;C 
cTnI 49 cats: 18 anemic, 
31 non-anemic, 
unwell controls 
cTnI higher in anemic cats than 
controls, but no correlation with PCV 
Immulite 
(Siemens) 
Lalor29 P;C 
  350 
Table 5: Summary of the studies reporting prognostic capability of cardiac biomarkers in cats 351 
cTnI, cardiac troponin I; NTproANP, N-terminal pro atrial natriuretic peptide; NTproBNP, N-terminal pro B-type natriuretic peptide; P, 352 
prospective study design; M, multicenter recruitment; C, control group appropriate; B, blinding specified in manuscript; E, 353 
echocardiography on all cats 354 
Test Number of cats Conclusions Assay Citation Study 
design 
NTproANP 68 cats: 25 heart 
disease/CHF, 26 
heart disease/NO-
CHF, 17 controls 
Increased NTproANP was associated 
with reduced survival time in 
univariable analysis, but lost 
significance in multivariable analysis 
when included with LA size.  
proANP 1-98 
(Biomedica 
Group, 
Immundiagnostik 
AG) 
Zimmering39 P;B;C;E 
cTnI 
cTnT 
36 cats with HCM (10 
cardiac death) 
23 healthy controls 
cTnI and cTnT were both higher in 
non-survivors than survivors. 
cTnI correlated with LVFW thickness 
at diagnosis 
ADVIA Centaur CP 
TnI-ultra 
(Siemens), Elecsys 
hs-TnT (Roche) 
Langhorn40 P;B;E 
NTproBNP 
cTnI 
41 cats with HCM (21 
cardiac death) 
cTnI provided prognostic information, 
independent of heart failure status 
and the presence of left atrial 
dilation. NTproBNP was significantly 
associated with prognosis only if 
heart failure status or LA size was not 
accounted for 
Cardiopet 
NTproBNP (2nd 
Gen; IDEXX), 
AccuTnI 
(Beckman 
Coulter) 
Borgeat41 P;B;E 
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Footnotes 356 
a http://www.ncbi.nlm.nih.gov/pubmed 357 
b http://wok.mimas.ac.uk/ 358 
c http://scholar.google.com / 359 
  360 
References 361 
 362 
1. Oyama MA. Using cardiac biomarkers in veterinary practice. Vet Clin North Am Small Anim 363 
Pract. 2013;43:1261-72, vi. 364 
2. Oyama MA, Boswood A, Connolly DJ, Ettinger SJ, Fox PR, Gordon SG, Rush JE, Sisson DD, 365 
Stepien RL, Wess G and Zannad F. Clinical usefulness of an assay for measurement of circulating N-366 
terminal pro-B-type natriuretic peptide concentration in dogs and cats with heart disease. J Am Vet 367 
Med Assoc. 2013;243:71-82. 368 
3. Connolly DJ, Cannata J, Boswood A, Archer J, Groves EA and Neiger R. Cardiac troponin I in 369 
cats with hypertrophic cardiomyopathy. J Feline Med Surg. 2003;5:209-16. 370 
4. Herndon WE, Rishniw M, Schrope D, Sammarco CD, Boddy KN and Sleeper MM. Assessment 371 
of plasma cardiac troponin I concentration as a means to differentiate cardiac and noncardiac causes 372 
of dyspnea in cats. J Am Vet Med Assoc. 2008;233:1261-4. 373 
5. Connolly DJ, Brodbelt DC, Copeland H, Collins S and Fuentes VL. Assessment of the 374 
diagnostic accuracy of circulating cardiac troponin I concentration to distinguish between cats with 375 
cardiac and non-cardiac causes of respiratory distress. Journal of veterinary cardiology : the official 376 
journal of the European Society of Veterinary Cardiology. 2009;11:71-8. 377 
6. Wells SM, Shofer FS, Walters PC, Stamoulis ME, Cole SG and Sleeper MM. Evaluation of 378 
blood cardiac troponin I concentrations obtained with a cage-side analyzer to differentiate cats with 379 
cardiac and noncardiac causes of dyspnea. J Am Vet Med Assoc. 2014;244:425-30. 380 
7. Fox PR, Oyama MA, Reynolds C, Rush JE, DeFrancesco TC, Keene BW, Atkins CE, Macdonald 381 
KA, Schober KE, Bonagura JD, Stepien RL, Kellihan HB, Nguyenba TP, Lehmkuhl LB, Lefbom BK, Moise 382 
NS and Hogan DF. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to 383 
distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. 384 
Journal of veterinary cardiology : the official journal of the European Society of Veterinary 385 
Cardiology. 2009;11 Suppl 1:S51-61. 386 
8. Connolly DJ, Soares Magalhaes RJ, Fuentes VL, Boswood A, Cole G, Boag A and Syme HM. 387 
Assessment of the diagnostic accuracy of circulating natriuretic peptide concentrations to distinguish 388 
between cats with cardiac and non-cardiac causes of respiratory distress. Journal of veterinary 389 
cardiology : the official journal of the European Society of Veterinary Cardiology. 2009;11 Suppl 390 
1:S41-50. 391 
9. Hassdenteufel E, Henrich E, Hildebrandt N, Stosic A and Schneider M. Assessment of 392 
circulating N-terminal pro B-type natriuretic peptide concentration to differentiate between cardiac 393 
from noncardiac causes of pleural effusion in cats. J Vet Emerg Crit Care (San Antonio). 2013;23:416-394 
22. 395 
10. Humm K, Hezzell M, Sargent J, Connolly DJ and Boswood A. Differentiating between feline 396 
pleural effusions of cardiac and non-cardiac origin using pleural fluid NT-proBNP concentrations. J 397 
Small Anim Pract. 2013;54:656-61. 398 
11. Janda S and Swiston J. Diagnostic accuracy of pleural fluid NT-pro-BNP for pleural effusions 399 
of cardiac origin: a systematic review and meta-analysis. BMC pulmonary medicine. 2010;10:58. 400 
12. Cortes R, Rivera M, Salvador A, Bertomeu V, de Burgos FG, Rosello-Lleti E, Portoles M, Paya 401 
R, Martinez-Dolz L and Climent V. Variability of NT-proBNP plasma and urine levels in patients with 402 
stable heart failure: a 2-year follow-up study. Heart. 2007;93:957-62. 403 
13. Herndon WE, Kittleson MD, Sanderson K, Drobatz KJ, Clifford CA, Gelzer A, Summerfield NJ, 404 
Linde A and Sleeper MM. Cardiac troponin I in feline hypertrophic cardiomyopathy. J Vet Intern Med. 405 
2002;16:558-64. 406 
14. Hsu A, Kittleson MD and Paling A. Investigation into the use of plasma NT-proBNP 407 
concentration to screen for feline hypertrophic cardiomyopathy. Journal of veterinary cardiology : 408 
the official journal of the European Society of Veterinary Cardiology. 2009;11 Suppl 1:S63-70. 409 
15. Wess G, Daisenberger P, Mahling M, Hirschberger J and Hartmann K. Utility of measuring 410 
plasma N-terminal pro-brain natriuretic peptide in detecting hypertrophic cardiomyopathy and 411 
differentiating grades of severity in cats. Vet Clin Pathol. 2011;40:237-44. 412 
16. Fox PR, Rush JE, Reynolds CA, Defrancesco TC, Keene BW, Atkins CE, Gordon SG, Schober KE, 413 
Bonagura JD, Stepien RL, Kellihan HB, Macdonald KA, Lehmkuhl LB, Nguyenba TP, Sydney Moise N, 414 
Lefbom BK, Hogan DF and Oyama MA. Multicenter evaluation of plasma N-terminal probrain 415 
natriuretic peptide (NT-pro BNP) as a biochemical screening test for asymptomatic (occult) 416 
cardiomyopathy in cats. J Vet Intern Med. 2011;25:1010-6. 417 
17. MacLean HN, Abbott JA, Ward DL, Huckle WR, Sisson DD and Pyle RL. N-terminal atrial 418 
natriuretic peptide immunoreactivity in plasma of cats with hypertrophic cardiomyopathy. J Vet 419 
Intern Med. 2006;20:284-9. 420 
18. Hori Y, Yamano S, Iwanaga K, Kano T, Tanabe M, Uechi M, Kanai K, Nakao R, Hoshi F and 421 
Higuchi S. Evaluation of plasma C-terminal atrial natriuretic peptide in healthy cats and cats with 422 
heart disease. J Vet Intern Med. 2008;22:135-9. 423 
19. Connolly DJ, Magalhaes RJ, Syme HM, Boswood A, Fuentes VL, Chu L and Metcalf M. 424 
Circulating natriuretic peptides in cats with heart disease. J Vet Intern Med. 2008;22:96-105. 425 
20. Zimmering TM, Meneses F, Nolte IJ and Simon D. Measurement of N-terminal proatrial 426 
natriuretic peptide in plasma of cats with and without cardiomyopathy. Am J Vet Res. 2009;70:216-427 
22. 428 
21. Machen MC, Oyama MA, Gordon SG, Rush JE, Achen SE, Stepien RL, Fox PR, Saunders AB, 429 
Cunningham SM, Lee PM and Kellihan HB. Multi-centered investigation of a point-of-care NT-proBNP 430 
ELISA assay to detect moderate to severe occult (pre-clinical) feline heart disease in cats referred for 431 
cardiac evaluation. Journal of Veterinary Cardiology. 432 
2014;http://dx.doi.org/10.1016/j.jvc2014.09.002. 433 
22. Langhorn R, Willesen JL, Tarnow I and Kjelgaard-Hansen M. Evaluation of a high-sensitivity 434 
assay for measurement of canine and feline serum cardiac troponin I. Vet Clin Pathol. 2013;42:490-8. 435 
23. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson 436 
RH, Apple FS, Ravkilde J and Wu AH. National Academy of Clinical Biochemistry Laboratory Medicine 437 
practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation. 438 
2007;116:e99-109. 439 
24. Connolly DJ, Guitian J, Boswood A and Neiger R. Serum troponin I levels in hyperthyroid cats 440 
before and after treatment with radioactive iodine. J Feline Med Surg. 2005;7:289-300. 441 
25. Menaut P, Connolly DJ, Volk A, Pace C, Luis Fuentes V, Elliott J and Syme H. Circulating 442 
natriuretic peptide concentrations in hyperthyroid cats. J Small Anim Pract. 2012;53:673-8. 443 
26. Sangster JK, Panciera DL, Abbott JA, Zimmerman KC and Lantis AC. Cardiac biomarkers in 444 
hyperthyroid cats. J Vet Intern Med. 2014;28:465-72. 445 
27. Porciello F, Rishniw M, Herndon WE, Birettoni F, Antognoni MT and Simpson KW. Cardiac 446 
troponin I is elevated in dogs and cats with azotaemia renal failure and in dogs with non-cardiac 447 
systemic disease. Australian veterinary journal. 2008;86:390-4. 448 
28. Lalor SM, Connolly DJ, Elliott J and Syme HM. Plasma concentrations of natriuretic peptides 449 
in normal cats and normotensive and hypertensive cats with chronic kidney disease. Journal of 450 
veterinary cardiology : the official journal of the European Society of Veterinary Cardiology. 2009;11 451 
Suppl 1:S71-9. 452 
29. Lalor SM, Gunn-Moore DA, Cash R, Foot A, Reed N and Mellanby RJ. Serum Cardiac Troponin 453 
I concentrations in cats with anaemia - a preliminary, single-centre observational study. J Small Anim 454 
Pract. 2014;55:320-2. 455 
30. Wagner T, Fuentes VL, Payne JR, McDermott N and Brodbelt D. Comparison of auscultatory 456 
and echocardiographic findings in healthy adult cats. Journal of veterinary cardiology : the official 457 
journal of the European Society of Veterinary Cardiology. 2010;12:171-82. 458 
31. Fernandes CJ, Jr., Akamine N and Knobel E. Cardiac troponin: a new serum marker of 459 
myocardial injury in sepsis. Intensive care medicine. 1999;25:1165-8. 460 
32. Langhorn R, Oyama M, King L, Machen M, Trafny D, Thawley V, Willesen JL, Tarnow I and 461 
Kjelgaard-Hansen M. Canine Cardiac Troponin I Significantly Complements Established Prognostic 462 
Composite Score in Dogs with Systemic Inflammation. Journal of Veterinary Internal Medicine. 463 
2012;26:713-713. 464 
33. Langhorn R, Oyama MA, King LG, Machen MC, Trafny DJ, Thawley V, Willesen JL, Tarnow I 465 
and Kjelgaard-Hansen M. Prognostic importance of myocardial injury in critically ill dogs with 466 
systemic inflammation. J Vet Intern Med. 2013;27:895-903. 467 
34. Moreno V, Hernandez-Romero D, Vilchez JA, Garcia-Honrubia A, Cambronero F, Casas T, 468 
Gonzalez J, Martinez P, Climent V, de la Morena G, Valdes M and Marin F. Serum levels of high-469 
sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. 470 
Journal of cardiac failure. 2010;16:950-6. 471 
35. Kubo T, Kitaoka H, Okawa M, Yamanaka S, Hirota T, Baba Y, Hayato K, Yamasaki N, 472 
Matsumura Y, Yasuda N, Sugiura T and Doi YL. Combined measurements of cardiac troponin I and 473 
brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic 474 
cardiomyopathy. Circulation journal : official journal of the Japanese Circulation Society. 475 
2011;75:919-26. 476 
36. Kubo T, Kitaoka H, Yamanaka S, Hirota T, Baba Y, Hayashi K, Iiyama T, Kumagai N, Tanioka K, 477 
Yamasaki N, Matsumura Y, Furuno T, Sugiura T and Doi YL. Significance of high-sensitivity cardiac 478 
troponin T in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62:1252-9. 479 
37. Geske JB, McKie PM, Ommen SR and Sorajja P. B-type natriuretic peptide and survival in 480 
hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61:2456-60. 481 
38. Coats CJ, Gallagher MJ, Foley M, O'Mahony C, Critoph C, Gimeno J, Dawnay A, McKenna WJ 482 
and Elliott PM. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in 483 
patients with hypertrophic cardiomyopathy. Eur Heart J. 2013;34:2529-37. 484 
39. Zimmering TM, Hungerbuhler S, Meneses F, Nolte I and Simon D. Evaluation of the 485 
association between plasma concentration of N-terminal proatrial natriuretic peptide and outcome 486 
in cats with cardiomyopathy. J Am Vet Med Assoc. 2010;237:665-72. 487 
40. Langhorn R, Tarnow I, Willesen JL, Kjelgaard-Hansen M, Skovgaard IM and Koch J. Cardiac 488 
Troponin I and T as Prognostic Markers in Cats with Hypertrophic Cardiomyopathy. J Vet Intern Med. 489 
2014. 490 
41. Borgeat K, Sherwood K, Payne JR, Luis Fuentes V and Connolly DJ. Plasma cardiac troponin I 491 
concentration and cardiac death in cats with hypertrophic cardiomyopathy. Journal of Veterinary 492 
Internal Medicine. 2014;in press. 493 
42. 2015 ACVIM Forum Research Abstract Program. Journal of Veterinary Internal Medicine. 494 
2015;29:1122-1256. 495 
 496 
